The polarization of immune cells in the tumour environment by TGFβ

[1]  Alberto Mantovani,et al.  Macrophages, innate immunity and cancer: balance, tolerance, and diversity. , 2010, Current opinion in immunology.

[2]  J. Berzofsky,et al.  Blockade of TGF‐β enhances tumor vaccine efficacy mediated by CD8+ T cells , 2010, International journal of cancer.

[3]  W. Zou,et al.  TH17 cells in tumour immunity and immunotherapy , 2010, Nature Reviews Immunology.

[4]  R. Blasberg,et al.  Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts , 2010, The Journal of experimental medicine.

[5]  P. Muranski,et al.  Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma , 2010, The Journal of experimental medicine.

[6]  Steven J. M. Jones,et al.  Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. , 2010, The New England journal of medicine.

[7]  Zhen-ping Zhu,et al.  Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells , 2010, Clinical Cancer Research.

[8]  Brian Bierie,et al.  Transforming growth factor beta (TGF-beta) and inflammation in cancer. , 2010, Cytokine & growth factor reviews.

[9]  N. Nagaraj,et al.  Targeting the transforming growth factor-β signaling pathway in human cancer , 2010, Expert opinion on investigational drugs.

[10]  L. Lanier,et al.  TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. , 2010, Neuro-oncology.

[11]  Y. Li,et al.  Immunotherapy for Human Renal Cell Carcinoma by Adoptive Transfer of Autologous Transforming Growth Factor β–Insensitive CD8+ T Cells , 2009, Clinical Cancer Research.

[12]  Yanping Zhang,et al.  Tumor Microenvironments Direct the Recruitment and Expansion of Human Th17 Cells , 2009, The Journal of Immunology.

[13]  J. Prieto,et al.  Peptide inhibitors of transforming growth factor‐β enhance the efficacy of antitumor immunotherapy , 2009, International journal of cancer.

[14]  P. Hwu,et al.  T helper 17 cells promote cytotoxic T cell activation in tumor immunity. , 2009, Immunity.

[15]  T. Giese,et al.  Tumour‐derived prostaglandin E2 and transforming growth factor‐β synergize to inhibit plasmacytoid dendritic cell‐derived interferon‐α , 2009, Immunology.

[16]  P. Allavena,et al.  Tumor‐associated macrophages (TAM) as major players of the cancer‐related inflammation , 2009, Journal of leukocyte biology.

[17]  J. Berzofsky,et al.  Synergistic Enhancement of CD8+ T Cell–Mediated Tumor Vaccine Efficacy by an Anti–Transforming Growth Factor-β Monoclonal Antibody , 2009, Clinical Cancer Research.

[18]  Edward R. Kastenhuber,et al.  Systemic Inhibition of Transforming Growth Factor-β in Glioma-Bearing Mice Improves the Therapeutic Efficacy of Glioma-Associated Antigen Peptide Vaccines , 2009, Clinical Cancer Research.

[19]  K. Stagliano,et al.  Cutting Edge: Tumor-Specific CD8+ T Cells Infiltrating Prostatic Tumors Are Induced to Become Suppressor Cells1 , 2009, The Journal of Immunology.

[20]  H. Salih,et al.  Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. , 2009, Cancer research.

[21]  B. Saha,et al.  Protumor vs Antitumor Functions of IL-171 , 2009, The Journal of Immunology.

[22]  B. Fox,et al.  Disruption of TGF-β Signaling Prevents the Generation of Tumor-Sensitized Regulatory T Cells and Facilitates Therapeutic Antitumor Immunity1 , 2009, The Journal of Immunology.

[23]  藤田 琢也.  Inhibition of transforming growth factor-β-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types , 2009 .

[24]  G. Cheng,et al.  Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. , 2009, Cancer cell.

[25]  G. Natoli,et al.  Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor κB , 2009, Proceedings of the National Academy of Sciences of the United States of America.

[26]  P. Validire,et al.  Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention. , 2009, Cancer research.

[27]  J. Berzofsky,et al.  The contrasting roles of NKT cells in tumor immunity. , 2009, Current molecular medicine.

[28]  R. Flavell,et al.  Opposing effects of TGF-beta and IL-15 cytokines control the number of short-lived effector CD8+ T cells. , 2009, Immunity.

[29]  D. Munn,et al.  Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. , 2009, Blood.

[30]  P. Muranski,et al.  Type 17 CD8+ T cells display enhanced antitumor immunity. , 2009, Blood.

[31]  J. Hanaoka,et al.  Inhibition of transforming growth factor-beta-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types. , 2009, Cancer research.

[32]  C. Dong,et al.  The IL-17/IL-23 axis of inflammation in cancer: friend or foe? , 2009, Current opinion in investigational drugs.

[33]  R. Schwendener,et al.  Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. , 2009, Cancer research.

[34]  M. A. Curotto de Lafaille,et al.  Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? , 2009, Immunity.

[35]  P. Allavena,et al.  Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. , 2009, Human immunology.

[36]  R. Steinman,et al.  Dendritic cells as controllers of antigen-specific Foxp3+ regulatory T cells. , 2009, Journal of dermatological science.

[37]  T. Mak,et al.  Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies , 2009, Nature Medicine.

[38]  S. Ménard,et al.  FOXP3 expression and overall survival in breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  P. Muranski,et al.  Adoptive immunotherapy of cancer using CD4(+) T cells. , 2009, Current opinion in immunology.

[40]  L. Wakefield,et al.  TGF-β modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression , 2009, Cancer Immunology, Immunotherapy.

[41]  S. Gordon,et al.  Alternative activation of macrophages: an immunologic functional perspective. , 2009, Annual review of immunology.

[42]  N. Senzer,et al.  Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients , 2009, Cancer Gene Therapy.

[43]  C. Münz,et al.  Dendritic Cell Interactions with NK Cells from Different Tissues , 2009, Journal of Clinical Immunology.

[44]  S. Howie,et al.  Human Dendritic Cells Produce TGF-β1 under the Influence of Lung Carcinoma Cells and Prime the Differentiation of CD4+CD25+Foxp3+ Regulatory T Cells1 , 2009, The Journal of Immunology.

[45]  R. Nurieva,et al.  Cutting Edge: In Vitro Generated Th17 Cells Maintain Their Cytokine Expression Program in Normal but Not Lymphopenic Hosts1 , 2009, The Journal of Immunology.

[46]  E. Podack,et al.  Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. , 2009, Cancer research.

[47]  C. Drake,et al.  Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. , 2009, Cancer cell.

[48]  T. Eberlein,et al.  Tumor-derived TGF-β Mediates Conversion of CD4+Foxp3+ Regulatory T Cells in a Murine Model of Pancreas Cancer , 2009, Journal of immunotherapy.

[49]  Xuetao Cao,et al.  Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-β11 , 2009, The Journal of Immunology.

[50]  Xuetao Cao,et al.  CD69+CD4+CD25− T Cells, a New Subset of Regulatory T Cells, Suppress T Cell Proliferation through Membrane-Bound TGF-β11 , 2009, The Journal of Immunology.

[51]  David Padua,et al.  Roles of TGFβ in metastasis , 2009, Cell Research.

[52]  N. Chaput,et al.  Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue , 2008, Gut.

[53]  G. Cheng,et al.  Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. , 2008, Cancer research.

[54]  R. Steinman,et al.  CD8+CD205+ Splenic Dendritic Cells Are Specialized to Induce Foxp3+ Regulatory T Cells1 , 2008, The Journal of Immunology.

[55]  J. Kapp,et al.  CD8+ suppressor T cells resurrected. , 2008, Human immunology.

[56]  K. Odunsi,et al.  Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer , 2008, Proceedings of the National Academy of Sciences.

[57]  P. Allavena,et al.  Macrophage polarization in tumour progression. , 2008, Seminars in cancer biology.

[58]  M. Caligiuri,et al.  TGF-β Utilizes SMAD3 to Inhibit CD16-Mediated IFN-γ Production and Antibody-Dependent Cellular Cytotoxicity in Human NK Cells1 , 2008, The Journal of Immunology.

[59]  D. McMurray,et al.  Altered inflammatory responses following transforming growth factor-beta neutralization in experimental guinea pig tuberculous pleurisy. , 2008, Tuberculosis.

[60]  R. Flavell,et al.  TGF-β: A Master of All T Cell Trades , 2008, Cell.

[61]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[62]  P. Muranski,et al.  Tumor-specific Th17-polarized cells eradicate large established melanoma. , 2008, Blood.

[63]  A. Chang,et al.  Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. , 2008, Cancer research.

[64]  D. Heitjan,et al.  Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. , 2008 .

[65]  S. Balk,et al.  Circulating Myeloid Dendritic Cells of Advanced Cancer Patients Result in Reduced Activation and a Biased Cytokine Profile in Invariant NKT Cells1 , 2008, The Journal of Immunology.

[66]  H. Heslop,et al.  Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-β Receptor , 2008, Journal of immunotherapy.

[67]  J. Niederkorn.  Emerging concepts in CD8(+) T regulatory cells. , 2008, Current opinion in immunology.

[68]  M. Veldhoen,et al.  Differentiation of human TH-17 cells does require TGF-β! , 2008, Nature Immunology.

[69]  J. Berzofsky,et al.  Phase I/II study of GC1008: A human anti-transforming growth factor-beta (TGF{beta}) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC) , 2008 .

[70]  J. Baselga,et al.  First human dose escalation study in patients with metastatic malignancies to determine safety and pharmacokinetics of LY2157299, a small molecule inhibitor of the transforming growth factor-beta receptor I kinase , 2008 .

[71]  S. Goerdt,et al.  Activation of a TGF-β-Specific Multistep Gene Expression Program in Mature Macrophages Requires Glucocorticoid-Mediated Surface Expression of TGF-β Receptor II1 , 2008, The Journal of Immunology.

[72]  J. Berzofsky,et al.  An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. , 2008, Cancer research.

[73]  Aleksandra M. Michalowska,et al.  Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. , 2008, Cancer research.

[74]  R. Ádány,et al.  Tumor‐infiltrating myeloid‐derived suppressor cells are pleiotropic‐inflamed monocytes/macrophages that bear M1‐ and M2‐type characteristics , 2008, Journal of leukocyte biology.

[75]  Lewis L Lanier,et al.  Up on the tightrope: natural killer cell activation and inhibition , 2008, Nature Immunology.

[76]  G. Tortora,et al.  LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis , 2008, Molecular Cancer Therapeutics.

[77]  J. Berzofsky,et al.  A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity , 2008, Cancer Immunology, Immunotherapy.

[78]  G. Halliday,et al.  TGFβ is responsible for skin tumour infiltration by macrophages enabling the tumours to escape immune destruction , 2008, Immunology and cell biology.

[79]  H. Hurwitz,et al.  VEGF Inhibition for Cancer Therapy , 2008 .

[80]  A. Palucka,et al.  Interactions of tumor cells with dendritic cells: balancing immunity and tolerance , 2008, Cell Death and Differentiation.

[81]  Lloyd J. Old,et al.  CD8+ Foxp3+ Regulatory T Cells Mediate Immunosuppression in Prostate Cancer , 2007, Clinical Cancer Research.

[82]  P. Khaw,et al.  A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. , 2007, Ophthalmology.

[83]  R. Steinman,et al.  Taking dendritic cells into medicine , 2007, Nature.

[84]  Y. Wan,et al.  Transforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy , 2007, Clinical Cancer Research.

[85]  J. M. Smith,et al.  Inhibition of human neutrophil degranulation by transforming growth factor‐β1 , 2007, Clinical and experimental immunology.

[86]  Zhao-You Tang,et al.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  A. Chang,et al.  Cutting Edge: Th17 and Regulatory T Cell Dynamics and the Regulation by IL-2 in the Tumor Microenvironment1 , 2007, The Journal of Immunology.

[88]  Juswinder Singh,et al.  A Novel Small-Molecule Inhibitor of Transforming Growth Factor β Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection , 2007 .

[89]  Ximing J. Yang,et al.  Tumor Evasion of the Immune System by Converting CD4+CD25− T Cells into CD4+CD25+ T Regulatory Cells: Role of Tumor-Derived TGF-β , 2007, The Journal of Immunology.

[90]  Kazunori Kataoka,et al.  Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling , 2007, Proceedings of the National Academy of Sciences.

[91]  R. Steinman,et al.  Dendritic cells with TGF-β1 differentiate naïve CD4+CD25− T cells into islet-protective Foxp3+ regulatory T cells , 2007, Proceedings of the National Academy of Sciences.

[92]  Drew M. Pardoll,et al.  Immunostimulatory monoclonal antibodies for cancer therapy , 2007, Nature Reviews Cancer.

[93]  K. Miyazono,et al.  Ki26894, a novel transforming growth factor‐β type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line , 2007, Cancer science.

[94]  O. Lantz,et al.  CD4 cells can be more efficient at tumor rejection than CD8 cells. , 2005, Blood.

[95]  J. Mantil,et al.  Phase I clinical trial of a TGF-β antisense-modified tumor cell vaccine in patients with advanced glioma , 2006, Cancer Gene Therapy.

[96]  A. Sica,et al.  p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. , 2006, Cancer research.

[97]  R. Akhurst,et al.  TGF beta inhibition for cancer therapy. , 2006, Current cancer drug targets.

[98]  R. Steinman,et al.  Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. , 2006, Blood.

[99]  N. Senzer,et al.  Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  Christopher Chiu,et al.  Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis , 2006, Proceedings of the National Academy of Sciences.

[101]  M. Beyer,et al.  Regulatory T cells in cancer. , 2006, Blood.

[102]  K. Mills,et al.  Suppression of Antitumor Immunity by IL-10 and TGF-β-Producing T Cells Infiltrating the Growing Tumor: Influence of Tumor Environment on the Induction of CD4+ and CD8+ Regulatory T Cells1 , 2006, The Journal of Immunology.

[103]  Ximing J. Yang,et al.  Blockade of transforming growth factor-β signaling in tumor-reactive CD8+ T cells activates the antitumor immune response cycle , 2006, Molecular Cancer Therapeutics.

[104]  Aleksandra M. Michalowska,et al.  Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. , 2006, Cancer research.

[105]  A. M. Hicks,et al.  Transferable anticancer innate immunity in spontaneous regression/complete resistance mice , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[106]  H. Kawai,et al.  Tumor-Derived TGFβ-1 Induces Dendritic Cell Apoptosis in the Sentinel Lymph Node , 2006, The Journal of Immunology.

[107]  S. Wahl,et al.  The kiss of death: interrupted by NK-cell close encounters of another kind. , 2006, Trends in immunology.

[108]  Richard A Flavell,et al.  Transforming growth factor-beta regulation of immune responses. , 2006, Annual review of immunology.

[109]  A. Sica,et al.  A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). , 2006, Blood.

[110]  U. Bogdahn,et al.  Targeted tumor therapy with the TGF-β2 antisense compound AP 12009 , 2006 .

[111]  C. Hill,et al.  Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. , 2006, Cytokine & growth factor reviews.

[112]  P. Basse,et al.  Antitumor activity of NK cells , 2006, Immunologic research.

[113]  R. Puri,et al.  IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis , 2006, Nature Medicine.

[114]  J. Massagué,et al.  TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. , 2005, Cancer cell.

[115]  B. Chauffert,et al.  Tumor cells convert immature myeloid dendritic cells into TGF-β–secreting cells inducing CD4+CD25+ regulatory T cell proliferation , 2005, The Journal of experimental medicine.

[116]  J. Xiang,et al.  CD4−8− Dendritic Cells Prime CD4+ T Regulatory 1 Cells to Suppress Antitumor Immunity1 , 2005, The Journal of Immunology.

[117]  U. Bogdahn,et al.  Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety. , 2005, Oligonucleotides.

[118]  F. Hoffmann,et al.  Selective inhibition of TGF-β responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP , 2005, Oncogene.

[119]  F. Sutterwala,et al.  Transforming growth factor-β controls T helper type 1 cell development through regulation of natural killer cell interferon-γ , 2005, Nature Immunology.

[120]  S. Rosenberg,et al.  TGF-β1 Attenuates the Acquisition and Expression of Effector Function by Tumor Antigen-Specific Human Memory CD8 T Cells , 2005, Journal of Immunology.

[121]  Ximing J. Yang,et al.  Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. , 2005, Cancer research.

[122]  R. Scolyer,et al.  Transforming growth factor-β1 immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system , 2005, Cancer Immunology, Immunotherapy.

[123]  K. Knutson,et al.  Tumor antigen-specific T helper cells in cancer immunity and immunotherapy , 2005, Cancer Immunology, Immunotherapy.

[124]  P. Richardson,et al.  Transforming Growth Factor β Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment , 2004, Clinical Cancer Research.

[125]  Dong-Wan Kim,et al.  Elevated TGF-b1 Secretion and Downmodulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients , 2004 .

[126]  M. Weller,et al.  SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo , 2004, Cancer Research.

[127]  J. S. Sawyer.  Synthesis and Activity of New Aryl‐ and Heteroaryl‐Substituted 5,6‐Dihydro‐4H‐pyrrolo[1,2‐b]pyrazole Inhibitors of the Transforming Growth Factor‐β Type I Receptor Kinase Domain. , 2004 .

[128]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[129]  K. Schlingensiepen,et al.  The TGF-beta1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: Preclinical studies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  R. Campbell,et al.  Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. , 2004, Bioorganic & medicinal chemistry letters.

[131]  R. Steinman,et al.  CD25+ CD4+ T Cells, Expanded with Dendritic Cells Presenting a Single Autoantigenic Peptide, Suppress Autoimmune Diabetes , 2004, The Journal of experimental medicine.

[132]  Peter R. Galle,et al.  Cutting Edge: TGF-β Induces a Regulatory Phenotype in CD4+CD25− T Cells through Foxp3 Induction and Down-Regulation of Smad7 , 2004, The Journal of Immunology.

[133]  L. Kaer,et al.  NKT cells: what's in a name? , 2004, Nature Reviews Immunology.

[134]  Li Li,et al.  Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 , 2003, The Journal of experimental medicine.

[135]  M. Tada,et al.  Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression. , 2003, The American journal of pathology.

[136]  J. Berzofsky,et al.  Transforming Growth Factor-β Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte–mediated Tumor Immunosurveillance , 2003, The Journal of Experimental Medicine.

[137]  J. Massagué,et al.  Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer , 2003, Nature Reviews Cancer.

[138]  R. Steinman,et al.  Direct Expansion of Functional CD25+ CD4+ Regulatory T Cells by Antigen-processing Dendritic Cells , 2003, The Journal of experimental medicine.

[139]  G. Remuzzi,et al.  J Am Soc Nephrol 14: 1816–1824, 2003 Add-On Anti–TGF- � Antibody to ACE Inhibitor Arrests Progressive Diabetic Nephropathy in the Rat , 2022 .

[140]  R. Biassoni,et al.  Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[141]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[142]  M. Roncarolo,et al.  The Role of IL-10 and TGF-β in the Differentiation and Effector Function of T Regulatory Cells , 2002, International Archives of Allergy and Immunology.

[143]  I. Frazer,et al.  Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. , 2002, Cancer research.

[144]  A. Reith,et al.  SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. , 2002, Molecular pharmacology.

[145]  L. Wakefield,et al.  Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. , 2002, The Journal of clinical investigation.

[146]  R. Flavell,et al.  Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells , 2001, Nature Medicine.

[147]  Michel C. Nussenzweig,et al.  Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo , 2001, The Journal of experimental medicine.

[148]  G. Halliday,et al.  Transforming growth factor-beta produced by progressor tumors inhibits, while IL-10 produced by regressor tumors enhances, Langerhans cell migration from skin. , 2001, International immunology.

[149]  Ira Mellman,et al.  Dendritic Cells Specialized and Regulated Antigen Processing Machines , 2001, Cell.

[150]  H Nagura,et al.  Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. , 2001, Cancer research.

[151]  O. Finn,et al.  Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. , 2001, Cancer research.

[152]  P. Schlag,et al.  Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. , 2001, Cancer research.

[153]  P. Musiani,et al.  The intriguing role of polymorphonuclear neutrophils in antitumor reactions. , 2001, Blood.

[154]  M. Roncarolo,et al.  Differentiation of T Regulatory Cells by Immature Dendritic Cells , 2001, The Journal of experimental medicine.

[155]  Jay A. Berzofsky,et al.  NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway , 2000, Nature Immunology.

[156]  R. Flavell,et al.  Abrogation of TGFβ Signaling in T Cells Leads to Spontaneous T Cell Differentiation and Autoimmune Disease , 2000 .

[157]  William B. Smith,et al.  Transforming growth factor-beta 1 inhibits the production of IL-8 and the transmigration of neutrophils through activated endothelium. , 1996, Journal of immunology.

[158]  H. Maeda,et al.  TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. , 1996, Journal of immunology.

[159]  H. Schreiber,et al.  Inhibition of tumor growth by elimination of granulocytes , 1995, The Journal of experimental medicine.

[160]  M. Colombo,et al.  Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma , 1993, The Journal of experimental medicine.

[161]  H. Fujiwara,et al.  Transforming growth factor-beta (TGF-beta)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-beta and a progressive increase in TGF-beta susceptibility of anti-tumor CD4+ T cell function. , 1993, Japanese journal of cancer research : Gann.

[162]  M. Colombo,et al.  Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. , 1992, Cancer research.

[163]  M. Sporn,et al.  Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. , 1986, Journal of immunology.

[164]  K. Johnson.  An Update. , 1984, Journal of food protection.